Nipun Davar joined Astex Pharmaceuticals, Inc. in February 2016. He has 20 years of experience in product development in the pharmaceutical industry, particularly process chemistry, formulation development, analytical sciences, and manufacturing. He joined Astex from Threshold Pharmaceuticals where he was a Corporate Officer, Senior Vice President and a member of the executive management team, and led the pharmaceutical development of the company’s lead oncology product, TH-302. From 2006 to 2011, he was Vice President of pharmaceutical sciences with Transcept Pharmaceuticals where he led the technical product development of Intermezzo® (low dose sublingual zolpidem tartrate), approved by the FDA for the treatment of middle-of-the-night insomnia. From 1996 to 2006, Nipun held various leadership positions at ALZA, latterly as Senior Director and Research Fellow, where he led multidisciplinary teams responsible for the approval of Jurnista® (OROS hydromorphone) in Europe and Invega® (OROS paliperidone) in the U.S. He has authored 13 issued or pending patents and multiple publications in the area of drug delivery and product development. Dr. Davar holds a Ph.D. in Pharmaceutical Sciences from the University of Maryland and an MBA from the Wharton School at the University of Pennsylvania.